136 related articles for article (PubMed ID: 7028944)
1. Therapy for urolithiasis with hydroxamic acids. IV. Prevention of infected urinary stone formation with N-(pivaloyl)glycinohydroxamic acid.
Satoh M; Munakata K; Kitoh K; Seto N; Kanazawa T; Takeuchi H; Yoshida O
J Pharmacobiodyn; 1981 Jul; 4(7):469-74. PubMed ID: 7028944
[TBL] [Abstract][Full Text] [Related]
2. Treatment of infected urinary stones in rats by a new hydroxamic acid, "N-(pivaloyl)glycinohydroxamic acid.
Takeuchi H; Okada Y; Kobashi K; Yoshida O
Urol Res; 1982; 10(4):217-9. PubMed ID: 6758273
[TBL] [Abstract][Full Text] [Related]
3. Prevention of infected urinary stones in rats by urease inhibitor: a new hydroxamic acid derivative.
Takeuchi H; Kobashi K; Yoshida O
Invest Urol; 1980 Sep; 18(2):102-5. PubMed ID: 6997228
[TBL] [Abstract][Full Text] [Related]
4. [Prevention of infected urinary stones by urease inhibitor. IV. Treatment of infection stones in rats by a new hydroxamic acid and cefalexin].
Takeuchi H; Tomoyoshi T; Okada Y; Yoshida O; Kobashi K
Hinyokika Kiyo; 1983 Mar; 29(3):297-302. PubMed ID: 6375315
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of effects of novel urease inhibitor, N-(pivaloyl)glycinohydroxamic acid on the formation of an infection bladder stone using a newly designed urolithiasis model in rats.
Satoh M; Munakata K; Takeuchi H; Yoshida O; Takebe S; Kobashi K
Chem Pharm Bull (Tokyo); 1991 Apr; 39(4):894-6. PubMed ID: 1893494
[TBL] [Abstract][Full Text] [Related]
6. Therapy for urolithiasis by hydroxamic acids. III. Urease inhibitory potency and urinary excretion rate of N-acylglycinohydroxamic acids.
Munakata K; Kobashi K; Takebe S; Hase J
J Pharmacobiodyn; 1980 Sep; 3(9):451-6. PubMed ID: 7007614
[TBL] [Abstract][Full Text] [Related]
7. Therapy for urolithiasis by hydroxamic acids. II. Urease inhibitory potency and urinary excretion rate of hippurohydroxamic acid derivatives.
Kobashi K; Munakata K; Takebe S; Hase J
J Pharmacobiodyn; 1980 Sep; 3(9):444-50. PubMed ID: 7007613
[TBL] [Abstract][Full Text] [Related]
8. Benurestat, a urease inhibitor for the therapy of infected ureolysis.
Andersen JA
Invest Urol; 1975 Mar; 12(5):381-6. PubMed ID: 1089613
[TBL] [Abstract][Full Text] [Related]
9. [Urinary calculi and infection].
Trinchieri A
Urologia; 2014; 81(2):93-8. PubMed ID: 24874306
[TBL] [Abstract][Full Text] [Related]
10. Computerized in vivo research from the growth of urease-producing bacteria in the presence of antibiotics combined with propionhydroxamic acid.
Rizzo M; Nicoletti P; Bartoletti R; Luciani E
Contrib Nephrol; 1987; 58():219-21. PubMed ID: 3319403
[No Abstract] [Full Text] [Related]
11. Prevention of infected urinary stones by urease inhibition.
Griffith DP; Musher DM
Invest Urol; 1973 Nov; 11(3):228-33. PubMed ID: 4584162
[No Abstract] [Full Text] [Related]
12. Inhibition of bacterial urease.
Griffith DP; Musher DM; Campbell JW
Invest Urol; 1973 Nov; 11(3):234-8. PubMed ID: 4201416
[No Abstract] [Full Text] [Related]
13. Stone formation by Ureaplasma urealyticum in human urine and its prevention by urease inhibitors.
Takebe S; Numata A; Kobashi K
J Clin Microbiol; 1984 Nov; 20(5):869-73. PubMed ID: 6549013
[TBL] [Abstract][Full Text] [Related]
14. Role of urease in pyelonephritis resulting from urinary tract infection with Proteus.
Musher DM; Griffith DP; Yawn D; Rossen RD
J Infect Dis; 1975 Feb; 131(2):177-81. PubMed ID: 234993
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of crystallization caused by Proteus mirabilis during the development of infectious urolithiasis by various phenolic substances.
Torzewska A; Rozalski A
Microbiol Res; 2014; 169(7-8):579-84. PubMed ID: 24239192
[TBL] [Abstract][Full Text] [Related]
16. Vaccines for Proteus mirabilis in urinary tract infection.
Li X; Mobley HL
Int J Antimicrob Agents; 2002 Jun; 19(6):461-5. PubMed ID: 12135833
[TBL] [Abstract][Full Text] [Related]
17. Ureaplasma urealyticum-induced crystallization of magnesium ammonium phosphate and calcium phosphates in synthetic urine.
Grenabo L; Brorson JE; Hedelin H; Pettersson S
J Urol; 1984 Oct; 132(4):795-9. PubMed ID: 6381769
[TBL] [Abstract][Full Text] [Related]
18. Deacidification by FhlA-dependent hydrogenase is involved in urease activity and urinary stone formation in uropathogenic Proteus mirabilis.
Lin WY; Liaw SJ
Sci Rep; 2020 Nov; 10(1):19546. PubMed ID: 33177598
[TBL] [Abstract][Full Text] [Related]
19. The effect of acetohydroxamic acid on the induction of bacterial ureases.
Rosenstein I; Hamilton-Miller JM; Brumfitt W
Invest Urol; 1980 Sep; 18(2):112-4. PubMed ID: 6997229
[TBL] [Abstract][Full Text] [Related]
20. [Acetylhydroxamic acid in the treatment of nephrolithiasis, caused by infection with urease forming microorganisms].
Lorenz J; Lorenz K; Dabrowska B; Kowal R
Z Urol Nephrol; 1989 Dec; 82(12):685-9. PubMed ID: 2698024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
